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ABSTRACT
Introduction: Dose escalation with tumor
necrosis factor (TNF)-blockers is poorly
characterized in pharmacy benefit
management (PBM) settings.
Methods: This retrospective study used
integrated pharmacy and medical claims from
the PBM Medco to characterize dose escalation
among rheumatoid arthritis (RA) patients treated
with etanercept and adalimumab. Data from
adults with RA with pharmacy claims for
etanercept or adalimumab between 1/1/2007
and 12/31/2009 and continuous enrollment for
C6 months before and C12 months after first
(index) pharmacy claim were analyzed. ‘‘New’’
patients had no claim for TNF-blocker in the
6 months prior to receipt of their index TNF-
blocker; otherwise, they were classified as
‘‘continuing’’ patients. Endpoints included
12-month persistence and duration on index
medication and dose escalation. Dose escalation
(allowed per adalimumab label but not for
etanercept) in patients’ persistent C12 months
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was estimated using five methods: (1) average
weekly dose C110% of recommended label dose;
(2) average subsequent dose C130% of starting
dose; (3) last dose C110% of starting dose; (4) C2
consecutive instances of dose C130% of starting
dose; and (5) any instance where dose increase
connoted an additional syringe/vial use.
Results: Data from 1,260 patients on
etanercept and 852 patients on adalimumab
were analyzed; 45.3 and 45.9% of new patients
on etanercept and adalimumab, respectively,
and 60.5 and 60.8% of continuing patients had
C12 months persistence on index medication.
Across all five methods used to estimate dose
escalation, patients receiving etanercept had
significantly lower rates of dose escalation
(P\0.001) than patients receiving
adalimumab. For new patients, rates of dose
escalation were 0.4–1.2% for etanercept and
8.3–14.1% for adalimumab. For continuing
patients, rates ranged from 1.1 to 2.9% for
etanercept and 7.0–28.3% for adalimumab.
Conclusions: New and continuing patients
from this PBM database on etanercept had
significantly lower rates of dose escalation
than patients on adalimumab.
Keywords: Adalimumab; Dose escalation;
Etanercept; Pharmacy benefit management;
Rheumatoid arthritis
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic,
inflammatory, autoimmune disease that
manifests primarily in the synovial tissues,
with symptoms of pain, stiffness, swelling, and
progressive joint destruction. Since 2002,
treatment recommendations for RA have
suggested an aggressive approach to inhibit
the progression of joint damage and other
complications that may develop soon after
diagnosis [1–3]. This aggressive approach
includes initiation of standard disease-
modifying antirheumatic drugs (DMARDs) and
biologic agents. Biologic agents target specific
mediators of RA, including the inflammatory
cytokine tumor necrosis factor (TNF) [4].
Etanercept is a TNF receptor:Fc fusion protein
and adalimumab is a recombinant human
monoclonal antibody against TNF.
The most commonly prescribed self-injected
TNF-blockers currently used in the treatment of
moderate to severe RA are etanercept and
adalimumab [5]. The United States (US) Food
and Drug Administration (FDA)-recommended
starting dose of etanercept for the treatment of
moderate to severe RA is 50 mg weekly
administered as a subcutaneous (SC) injection
[6]. The recommended dose of adalimumab is
40 mg every other week (EOW) administered
SC, which can be increased to 40 mg weekly for
patients not on concomitant methotrexate [7].
Data from observational and clinical studies
have shown that some patients require an
upward dose adjustment or shortened dose
interval to achieve or maintain a clinical
response to some TNF-blockers [8–15].
Information on dosing patterns used in the
real-world clinical setting would be useful to
estimate the cost of treatment for RA with these
agents to assist in formulary and reimbursement
decision-making [16].
Analyses of dose escalation using data from
commercial health plans estimated that rates of
TNF-blocker dose escalation range from 1 to
18% for patients on etanercept and 8–33% for
patients on adalimumab [10–12, 17–22]. In the
US, Pharmacy Benefit Management (PBM)
companies act as third-party administrators to
manage the cost and utilization of prescription
drugs and benefits. The wide variety of
utilization management strategies and tools
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applied by the PBM may impact the utilization
and dosing patterns of TNF-blockers. The
objective of this study was to estimate
persistence, utilization patterns, and dose
escalation rates of etanercept and adalimumab
among patients with RA in a PBM setting,
including patients newly initiating treatment
and those continuing on therapy.
MATERIALS AND METHODS
Study Design and Setting
This retrospective analysis utilized
administrative claims data from Medco, a
large, geographically diverse PBM that covers
over 60 million patients in the US, supporting
commercial health plans, employers, and
federal and state governments. An integrated
database of both medical and pharmacy claims
was available for 10 million patients, and data
from July 1, 2006 to December 31, 2010 were
used in the analysis (Fig. 1). (Medco was
acquired by Express Scripts, Inc. in 2012, after
the study period.) The index date was the date
of the first observed prescription for the index
medication (etanercept or adalimumab) during
the study period. The pre-index period was the
6 months prior to the index date and the
follow-up period comprised a minimum of
12 months of continuous enrollment
following the index date. The study intake
period was from January 1, 2007 through to
December 31, 2009.
Eligibility Criteria
Patients were eligible for inclusion in the study
if they were aged 18–64 years; diagnosed with
RA (International Classification of Diseases—
Clinical Modification Code, 9th Revision [ICD-
9] code 714.0x) in the pre-index period;
prescribed etanercept or adalimumab during
the study intake period; and continuously
enrolled to receive pharmacy benefits for at
least 6 months prior to and at least 12 months
following their index date. Patients were
excluded from the analysis if they had a
diagnosis of psoriasis (ICD-9 code 696.1),
psoriatic arthritis (ICD-9 code 696.0), juvenile
idiopathic arthritis (ICD-9 code 714.3), Crohn’s
disease (ICD-9 code 555.x), ulcerative colitis
(ICD-9 code 556.x), ankylosing spondylitis (ICD-9
code 720.0), multiple sclerosis (ICD-9 code
340.xx), or lupus (ICD-9 code 710.0x) during
the pre-index period, or a diagnosis of HIV or
Fig. 1 Study schema. Dates for pre-index, study intake, and follow-up periods are shown
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cancer during the pre-index period or follow-up
period. Patients with in-office injection claims (J-
codes) during follow-up were excluded because it
was not possible to accurately estimate the
quantity of medication administered from the
data that were available. Patients were categorized
as new to therapy if they did not have any TNF-
blocker claims during the pre-index period and as
continuing therapy if they had a TNF-blocker
claim during the pre-index period.
Outcomes
Duration and persistence on index medication
as well as dose escalation rates of etanercept and
adalimumab were evaluated. Duration of index
therapy was defined as the time from the index
dose through the date of fill for the last
prescription in the follow-up period regardless
of gaps in the index therapy. Persistence was
measured as the number of days from the index
date to the first occurrence of either a gap in
index therapy of at least 60 days or a claim for
another biologic. Gaps in therapy were
identified as the time between the run-out of a
fill until the fill date of the next claim. Patients
with no gaps in therapy of at least 60 days and
no switches throughout their entire follow-up
were considered to have a length of persistence
equal to that of their follow-up period.
Dose escalation was evaluated in patients
who were persistent on their index TNF-
blocker for at least 12 months and who
started at or above the labeled dose. Dose
escalation was defined using five previously
published methods: (1) average weekly dose
C110% of the minimum FDA-recommended
label dose [11, 17]; (2) average subsequent
dose C130% of the starting dose [11]; (3) last
dose C110% of the starting dose [20]; (4) two
or more consecutive instances of a dose
C130% of the starting dose [11]; or (5) any
instance of a syringe or vial increase (change
in dose from 50 to 75 mg per week or from
50 to 100 mg per week for etanercept; change
from 40 mg EOW to 40 mg per week for
adalimumab) [23].
The average weekly dose during the
12 months after the index date and the total
dispensed quantity within those 12 months was
calculated for patients who were persistent on
index medication for at least 12 months. Costs
were calculated using the October 2012
Wholesale Acquisition Costs (WAC) for these
drugs [24].
This article does not contain any studies
with human or animal subjects performed by
any of the authors.
Statistical Considerations
Descriptive analyses of demographic and
clinical characteristics, dose escalation metrics,
and persistence patterns were examined
separately for patients in the etanercept and
adalimumab cohorts and were stratified by new
and continuing patients. Chi square tests were
used to evaluate the statistical significance of
differences for categorical variables; t tests and
analysis of variance were used for normally
distributed continuous variables. Statistical
analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA).
RESULTS
Patients
A total of 2,112 RA patients, including 1,023
new patients (572 etanercept; 451
adalimumab) and 1,089 continuing patients
(688 etanercept; 401 adalimumab), met the
eligibility criteria and were included in the
520 Adv Ther (2013) 30:517–527
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Fig. 2 Patient selection. Attrition of patients per eligibility criteria for new and continuing patients on etanercept and
adalimumab is shown
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analysis (Fig. 2). Demographic and clinical
characteristics were similar between patients
receiving etanercept and those receiving
adalimumab (Table 1).
Duration and Persistence on TNF-Blocker
Therapy
Mean [standard deviation, SD] duration of
index therapy was longer for continuing
patients (31.2 [17.1] months) than for new
patients (18.0 [13.7] months) and was similar
between treatments for new and continuing
patients (Table 2). Similarly, a greater
proportion of continuing patients had at least
12 months on index therapy (77.1 vs 58.1% for
new patients).
Mean persistence (SD) on index therapy was
15.0 (12.6) months in new patients and 23.3
(17.6) months in continuing patients and was
similar between etanercept and adalimumab
for new and continuing patients (Table 2). The
proportion of patients with persistence of
C12 months on index therapy was 45.6% in
Table 1 Demographics and comorbidity status of patients with rheumatoid arthritis who were new or continuing
etanercept or adalimumab therapy
New patients N5 1,023 Continuing patients N5 1,089
ETN n5 572 ADA n5 451 ETN n5 688 ADA n5 401
Age group (years), n (%)
18–25 12 (2.1) 6 (1.3) 11 (1.6) 2 (0.5)
26–35 44 (7.7) 28 (6.2) 25 (3.6) 16 (4.0)
36–45 106 (18.5) 84 (18.6) 85 (12.4) 59 (14.7)
46–55 210 (36.7) 169 (37.5) 256 (37.2) 119 (29.7)
56–64 200 (35.0) 164 (36.4) 311 (45.2) 205 (51.1)
Sex, n (%)
Female 461 (80.6) 366 (81.2) 546 (79.4) 310 (77.3)
Male 110 (19.2) 83 (18.4) 142 (20.6) 91 (22.7)
Missing 1 (0.2) 2 (0.4) 0 0
Region, n (%)
Northeast 64 (11.2) 70 (15.5) 96 (14.0) 68 (17.0)
Midwest 144 (25.2) 116 (25.7) 154 (22.4) 106 (26.4)
South 192 (33.6) 169 (37.5) 232 (33.7) 140 (34.9)
West 172 (30.1) 95 (21.1) 206 (29.9) 87 (21.7)
Missing 0 1 (0.2) 0 0
Quan-Charlson index, mean score [SD] 1.4 [0.7] 1.5 [0.9] 1.3 [0.8] 1.3 [0.7]
Received methotrexate in pre-index period, n (%) 361 (63.1) 298 (66.1) 344 (50.0) 234 (58.4)
ADA adalimumab, ETN etanercept, SD standard deviation
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new patients and 60.6% in continuing
patients.
Dose Escalation
Patients receiving etanercept had a
significantly lower rate of dose escalation
(range 0.4–2.9%) than those receiving
adalimumab (range 7.0–28.3%) according to
all five methods of calculating dose escalation
for both new and continuing patients
(P\0.001) (Table 3). Rates of dose escalation
were generally similar between new and
continuing patients.
Total Index Drug Utilization and Costs
The average weekly dose (SD) over the study
period for new patients was 49.3 (2.8) mg for
etanercept and 21.5 (4.9) mg for adalimumab.
The average weekly dose (SD) over the study
period for continuing patients was 49.6 (6.7) mg
for etanercept and 23.9 (7.4) mg for
adalimumab. The mean total dispensed
quantities (SD) within 12 months for new
patients were 2,631 (369) mg for etanercept
and 1,111 (269) mg for adalimumab. The mean
total dispensed quantities (SD) for continuing
patients were 2,539 (509) mg for etanercept and
1,176 (419) mg for adalimumab. The mean costs
Table 3 Dose escalation in rheumatoid arthritis patients who were persistent on index medication for C12 months,
starting at or above label dose
New patients Continuing patients
ETN ADA ETN ADA
Patients persistent for C12 months, starting at or above
recommended label dose, n
253 206 412 244
Dose escalation deﬁnition, n (%)
1. Average weekly dose C110% of recommended label dosea 2 (0.8) 29 (14.1) 12 (2.9) 69 (28.3)
2. Average subsequent dose C130% of starting dosea 1 (0.4) 17 (8.3) 5 (1.2) 17 (7.0)
3. Last dose C110% of starting dosea 2 (0.8) 21 (10.2) 5 (1.2) 21 (8.6)
4. Two or more consecutive instances of dose C130% of starting dosea 3 (1.2) 23 (11.2) 11 (2.7) 28 (11.5)
5. Syringe or vial increase or shortened frequency of dosinga 2 (0.8) 24 (11.7) 4 (1.0) 38 (15.6)
ADA adalimumab, ETN etanercept
a P\0.001 for comparison of etanercept versus adalimumab within new and continuing patients
Table 2 Duration and persistence on index medication among rheumatoid arthritis patients
New patients N5 1,023 Continuing patients N5 1,089
ETN n5 572 ADA n5 451 ETN n5 688 ADA n5 401
Mean duration of therapy, months [SD] 18.5 [14.0] 17.3 [13.3] 31.9 [17.0] 30.1 [17.2]
Patients with C12 months duration, n (%) 337 (58.9) 257 (57.0) 539 (78.3) 301 (75.1)
Mean persistence on therapy, months [SD] 15.0 [12.7] 15.0 [12.5] 23.4 [17.7] 23.0 [17.4]
Patients with C12 months persistence, n (%) 259 (45.3) 207 (45.9) 416 (60.5) 244 (60.8)
ADA adalimumab, ETN etanercept, SD standard deviation
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for new patients were US $27,205 for etanercept
and US $28,453 for adalimumab; the mean
costs for continuing patients were US $26,253
for etanercept and US $30,117 for adalimumab.
DISCUSSION
This prescription claims study of dose escalation
rates among patients with RA in a PBM setting
found significantly lower rates of dose
escalation for persistent patients receiving
etanercept compared with persistent patients
receiving adalimumab. For new patients,
proportions of patients escalating from the
FDA-recommended starting dose or higher
ranged from 0.4 to 1.2% for etanercept and
8.3 to 14.1% for adalimumab. For continuing
patients, proportions of patients escalating from
the FDA-recommended starting dose or higher
ranged from 1.1 to 2.9% for etanercept and 7.0
to 28.3% for adalimumab. Age, gender,
comorbidity index, and regional distributions
were similar between treatments, indicating
that these factors did not account for
differences in dose escalation. These results
suggest that etanercept dosing was stable and
predictable in patients receiving etanercept for
moderate to severe RA, whereas 8–14% of
patients receiving adalimumab experienced
dose escalation from their starting dose.
Consistent with the dose escalation results,
the average weekly dose over the study period
and the total dispensed quantities within
12 months for the patients who were
persistent on etanercept were close to the label
dose of 50 mg weekly. Higher rates of dose
escalation compared with etanercept were
observed, and average weekly doses and total
dispensed quantities of adalimumab were
slightly higher than the label dose. For new
patients on adalimumab, both measures were
approximately 7% higher than would be
expected from the label dose and for
continuing patients, the average weekly dose
was approximately 20% higher and total
dispensed quantity within the first year was
about 13% higher than the label dose.
In this study, five different methods of
calculating dose escalation were used; most of
these methods have been used in previously
published studies [11–13, 17, 20, 21]. We used a
real-world definition of dose escalation
(syringe/vial increase or shortened frequency
of dosing) and a method used in other studies
[13, 22] (average weekly dose) to compare
patterns across etanercept and adalimumab.
Results were consistent across five different
methods of estimating dose escalation, with
etanercept having lower dose escalation rates
than adalimumab.
The results presented here are consistent
with those reported from studies evaluating
dose escalation in commercial health plans.
Observational studies from this setting have
previously documented dose escalation rates of
0.8–7.9% for patients newly initiating
etanercept and 8–17.1% for patients newly
receiving adalimumab [10–13, 17, 20–22].
Across all studies, etanercept had the lowest
rate of dose escalation in new patients. In a
study that examined dose escalation in
continuing patients [12], dose escalation rates
were 3–4% for etanercept and 9–11% for
adalimumab.
A key strength of the study was the use of
real-world data from a PBM setting
representative of pharmacy benefits utilization
across small and large managed care
organizations, employer groups, and
government entities. Regardless of the method
used, results were consistent across all five
methods. The reason for dose escalation was
not captured in this database. One reason why
etanercept patients may have had lower rates of
524 Adv Ther (2013) 30:517–527
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dose escalation is that the US prescribing
information for etanercept only recommends
the 50 mg per week dose for the treatment of
moderate to severe RA. In contrast, the rate of
dose escalation with adalimumab was higher
and the US prescribing information includes the
option to increase the dose from 40 mg EOW to
40 mg weekly in patients not receiving
methotrexate. Whatever the reason, this
predictability of etanercept dosing may be
useful information for payors.
The primary limitation of the study was
inherent to the use of an administrative claims
database as a data source. Important clinical
information such as severity of disease, clinical
response to treatment, and the reason for dose
escalation is not captured in a claims database.
In addition, the accuracy of data in the claims
database is dependent on the pharmacist
entering the data and the physician writing
the prescription. This analysis involved only
etanercept and adalimumab utilization and was
not comprehensive of all biologics used to treat
RA. The study intake period ended in December
2009, and newer TNF-blocker therapies for RA
were not included in this analysis because too
few patients had received these therapies for
12 months. The amounts paid for prescriptions
were not available for this analysis, so an
association between dose escalation and payor
cost could not be calculated. The study
population was limited to patients with a
minimum of 18 months of continuous
enrollment and therefore, did not include
patients who were disenrolled from the PBM
during the study. This study may not be
generalizable to other RA populations, such as
Medicare, Veterans Affairs, underinsured, or
uninsured patients or be representative of the
total RA population in the US. Though the
dataset included patients from all 50 states and
was relatively well distributed geographically, it
was slightly over-weighted in Pennsylvania,
Ohio, and North Carolina and slightly under-
weighted in California, Texas, Florida, and
Illinois.
CONCLUSION
In conclusion, several different measures of
evaluating dose escalation were applied to data
from a PBM setting that represented the real-
world use of the TNF-blockers etanercept and
adalimumab. Each method consistently showed
that RA patients on etanercept had significantly
lower rates of dose escalation than patients on
adalimumab for both new and continuing
patients. These results support stable and
predictable dosing with etanercept in patients
with moderate to severe RA. Studies of real-
world treatment patterns can be useful to
payors performing cost analyses or to
managers of inventories of TNF-blockers used
for the treatment of RA.
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